In an­oth­er try at lung can­cer niche, J&J nabs a po­ten­tial Tagris­so ri­val for $50M-plus

Weeks af­ter bow­ing out of a bil­lion-dol­lar deal with Aduro Biotech, J&J is back to the draw­ing board with an­oth­er on­col­o­gy li­cens­ing pact that, if fruit­ful, could pit them di­rect­ly against As­traZeneca’s lung can­cer star Tagris­so.

Ko­re­an drug­mak­er Yuhan is col­lect­ing $50 mil­lion up­front on the deal, which cen­ters around laz­er­tinib, a third-gen­er­a­tion EGFR ty­ro­sine-ki­nase in­hibitor de­signed to tar­get mul­ti­ple mu­ta­tions of the re­cep­tor. With world­wide rights to the as­set — ex­cept for South Ko­rea — J&J will take over de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion while col­lab­o­rat­ing with Yuhan on clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER